Tocagen Inc

Tocagen — Forte Biosciences — Technical Presentation (July 2026)

21 slides from Tocagen's technical presentation, Jul 9, 2026

  1. Slide 1: Forte FB102 Phase 1b Vitiligo Data

    Forte FB102 Phase 1b Vitiligo Data July 9, 2026 Exhibit 99.2

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 2IE of the Securities and Exchange Act of 1934, as amended, and the Private Securities

  3. Slide 3: Large unmet need in vitiligo presents a substantial market opportunity

    Large unmet need in vitiligo presents a SUBSTANTIAL MARKET opportunity Vitiligo is an autoimmune disease of the skin driven by pathogenic T cells that kill melanocytes and create white spots Vitiligo results in sensitive skin (increasing likelihood of sun burns), eye abnormalities, emotional challen

  4. Slide 4: IL-15 activation of pathogenic CD8+ T cells in skin

    IL-15 activation of pathogenic CD8+ T cells in skin Vitiligo patients have unpigmented skin due activated pathogenic T cells killing melanocytes FB102 blocks activation of pathogenic T cells, restoring melanocyte health and skin pigmentation Tokura Front Immunol. 2021 PMID 33633737

  5. Slide 5: IL-2 Therapy drives vitiligo

    IL-2 Therapy drives vitiligo Journal of Investigative Derm. (2006) Vol 126 Journal of Clinical Oncology V19(15) Enhanced Survival Associated with Vitiligo Expression during Maintenance Biotherapy for Metastatic Melanoma(1) Peter D. Boasberg1, Dave S.B. Hoon2, Lawrence D. Piro1, Maureen A. Martin1, A

  6. Slide 6: An anti-CD122 antibody is effective in a mouse vitiligo model with established disease

    An anti-cd122 antibody is effective in a mouse vitiligo model with established disease Repigmentation study Richmond, 2012. Sci Transl Med. 2018 PMID 30021889 Melanin-reactive T cells eliminated pigment in tail Anti-CD122 treatment restored pigmentation Vehicle (control) treatment did not restore pi

  7. Slide 7: Anti-CD122 in a Mouse Model of Vitiligo: Potential of durable response with infrequent dosing

    Anti-CD122 in a Mouse Model of Vitiligo: Potential of durable response with Infrequent Dosing Regimen​ Note: anti-mouse CD122 (surrogate molecule) was used in these studies.

  8. Slide 8: FB102 Placebo Controlled Phase 1b Vitiligo

    FB102 Placebo Controlled Phase IB ViTIligo

  9. Slide 9: FB102-401 Double-Blind Placebo-Controlled Phase 1b Vitiligo Study Design

    FB102-401 DOUBLE-BLIND PLACEBO-CONTROLLED Phase 1b Vitiligo STUDY DESIGN Screening Includes Central Read FVASI Randomization 3:1 Ratio FB102:PBO Safety Follow-up Treatment Week 1 6 9 12 16 24 Follow-up Cohort B (17 subjects) Placebo (11 Subjects) R Cohort A (15 subjects) Central Read FVASI 12-week t

  10. Slide 10: Summary of FB102 Phase 1b Vitiligo Study

    Summary of FB102 Phase 1b Vitiligo STUDY The FB102 phase 1b double-blind placebo-controlled vitiligo study enrolled 43 subjects 3:1 randomized with 11 on placebo and 32 on FB102. The primary endpoint of the study was mean percent FVASI improvement from baseline at week 24 as assessed by central-revi

  11. Slide 11: ITT: Statistically significant primary endpoint of FVASI week 24 percent improvement

    ITT: STATISTICALLY SIGNIFICANT PRIMARY ENDPOINT OF Fvasi week 24 percent improvement from baseline: Intent to treat (ITT) population Week 24 Mean % Improvement FB102 PBO (ITT: N=11) PBO Adjusted p-value Cohort A (N=15) 28.8% -16.2% +45.0 pts 0.013 Cohort B (N=17) 30.4% -16.2% +46.6pts 0.009 FB102 (N

  12. Slide 12: EE: Statistically significant primary endpoint of FVASI week 24 percent improvement

    EE: STATISTICALLY SIGNIFICANT PRIMARY ENDPOiNT OF FVASI week 24 percent improvement from baseline: PROTOCOL-DEFI NED Efficacy evaluable (EE) population Week 24 Mean % Improvement FB102 PBO (EE: N=10) PBO Adjusted p-value Cohort A (N=15) 28.8% 7.9% +20.9 pts 0.040 Cohort B (N=17) 30.4% 7.9% +22.5pts

  13. Slide 13: Statistical significance achieved by day 64 and continued through 24 weeks

    STATISTICAL SIGNIFICANCE ACHIEVED BY DAY 64 and continued through 24 weeks with 12-Week TREATMENT FVASI mean % improvement FB102 (N=32) PBO (N=10) PBO-Adjusted p-value Week 6 5.6% 0.3% +5.3 pts 0.059 Week 9 (Day 64) 14.4% 1.9% +12.5 pts 0.023 Week 12 21.9% 5.4% +16.5 pts 0.028 Week 16 28.6% 8.2% +20

  14. Slide 14: Subjects with greater baseline vitiligo involvement outperformed on FB102

    SUBJECTs WITH GREATER BASELINE VITILIGO INVOLVEMENT OUTPERFORMED ON FB102 (baseline FVASI ≥0.75) FVASI mean % improvement FB102 (N=17) PBO (N=4) PBO-Adjusted p-value Week 6 7.2% 0.5% +6.7 pts 0.167 Week 9 (Day 64) 19.4% 1.2% +18.2 pts 0.058 Week 12 29.6% 1.7% +27.9 pts 0.033 Week 16 40.2% 1.5% +38.7

  15. Slide 15: FVASI improvement at week 24 vs competitors

    Fvasi improvement at week 24 vs competitors (Phase 2 data) 5 Passeron T, et al. eClinicalMedicine. 2024 Pandya AG, et al. J Am Acad Dermatol. 2025 Ezzedine K, et al. J Am Acad Dermatol. 2023

  16. Slide 16: Week 24 FVASI50 and FVASI75 data

    Week 24 Fvasi50 and fvasi75 data Population FVASI50 FB102 FVASI50 PBO FVASI75 FB102 FVASI75 PBO Protocol Defined Efficacy-evaluable 11/32 (34.4%) 1/10 (10.0%) 4/32 (12.5%) 1/10 (10.0%) Baseline FVASI ≥0.75 10/17 (58.8%) 0/4 (0.0%) 4/17 (23.5%) 0/4 (0.0%) FB102 achieved FVASI50 of 58.8% in FVASI ≥0.7

  17. Slide 17: FVASI50 at week 24 vs competitors

    Fvasi50 at week 24 vs competitors (Phase 2 Data) Passeron T, et al. eClinicalMedicine. 2024 Pandya AG, et al. J Am Acad Dermatol. 2025 Ezzedine K, et al. J Am Acad Dermatol. 2023

  18. Slide 18: FVASI75 at week 24 vs competitors

    Fvasi75 at week 24 vs competitors (Phase 2 data) Passeron T, et al. eClinicalMedicine. 2024 Pandya AG, et al. J Am Acad Dermatol. 2025 Ezzedine K, et al. J Am Acad Dermatol. 2023

  19. Slide 19: FB102 re-pigmentation

    FB102 re-pigmentation Baseline FVASI = 0.75 Week 12 FVASI = 0.20 73% improvement Week 24 FVASI = 0.10 87% improvement

  20. Slide 20: FB102-401 continues to demonstrate strong safety profile

    FB102-401 CONTINUES TO DEMONSTRATE STRONG Safety PROFILE Safety FB102 Placebo ≥1 TEAE 25/32 (78.1%) 9/11 (81.8%) Mild (Grade 1) 23/32 (71.9%) 9/11 (81.8%) Moderate (Grade 2) 18/32 (56.3%) 6/11 (54.5%) Severe (≥ Grade 3) 0 0 FB102 continues to demonstrate a strong safety profile and compared favorabl

  21. Slide 21: Summary

    SummaRY In double-blind placebo-controlled study, FB102 demonstrated robust activity, with statistically significant improvement in vitiligo from baseline to week 24, statistically significant responses occurring early (day 64), robust responder analysis, and continuing improvement through week 24 a

Forte Biosciences — Technical Presentation (July 2026) on 6ix